CN113730396A - Application of oroxylin in preparation of pancreatic cancer treatment medicine - Google Patents
Application of oroxylin in preparation of pancreatic cancer treatment medicine Download PDFInfo
- Publication number
- CN113730396A CN113730396A CN202111085855.5A CN202111085855A CN113730396A CN 113730396 A CN113730396 A CN 113730396A CN 202111085855 A CN202111085855 A CN 202111085855A CN 113730396 A CN113730396 A CN 113730396A
- Authority
- CN
- China
- Prior art keywords
- oroxylin
- pancreatic cancer
- tumor
- application
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 33
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 33
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 33
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- 238000002474 experimental method Methods 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 12
- 238000011580 nude mouse model Methods 0.000 abstract description 12
- 238000010171 animal model Methods 0.000 abstract description 9
- 230000009982 effect on human Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 26
- 230000000694 effects Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention discloses application of oroxylin in preparation of a pancreatic cancer treatment drug, and belongs to the technical field of medicines. The invention verifies that the oroxylin has good inhibition effect on human pancreatic cancer BxPC-3 cells through MTT experiments and nude mouse ectopic tumor inhibition experiments, and has no obvious influence on the weight of experimental animals. The application shows that the oroxylin has good application prospect in treating pancreatic cancer and can be used for preparing pancreatic cancer treatment medicines.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of oroxylin in preparation of a pancreatic cancer treatment medicine.
Background
Oroxylin A is one of active components of radix Scutellariae, has obvious antitumor effect, and is a natural antitumor drug with wide application prospect. However, oroxylin has wide pharmacological action, the mechanism of the anti-tumor action of oroxylin is not completely clarified at present, and documents show that oroxylin can play the anti-tumor action by inducing apoptosis of tumor cells and also has the action of inhibiting growth of tumor blood vessels. Meanwhile, the anticancer effect of oroxylin is different from that of common chemotherapeutic anticancer drugs, can selectively kill tumor cells, has little influence on the normal hematopoietic system, and is not possessed by the current tumor chemotherapeutic drugs.
Pancreatic cancer is a malignant tumor of the digestive tract that is highly malignant and difficult to diagnose and treat. In recent years, the morbidity and mortality of the tumor are obviously increased, and the 5-year survival rate is less than 1 percent, which is one of the worst malignant tumors in prognosis. The early diagnosis rate of pancreatic cancer is low, the operative mortality rate is high, the cure rate is low, and effective treatment medicines are lacked.
At present, reports of preparing pancreatic cancer treatment medicines by using oroxylin do not appear.
Disclosure of Invention
The invention aims to provide application of oroxylin in preparation of a pancreatic cancer treatment drug.
The invention verifies that the oroxylin has good inhibition effect on human pancreatic cancer BxPC-3 cells through MTT experiments and nude mouse ectopic tumor inhibition experiments, and has no obvious influence on the weight of experimental animals. The application shows that the oroxylin has good application prospect in treating pancreatic cancer and can be used for preparing pancreatic cancer treatment medicines.
Drawings
FIG. 1 shows the effect of oroxylin on the growth viability of pancreatic cancer cell line BxPC3 in example 1.
FIG. 2 shows the effect of oroxylin on the tumor volume of nude mice xenografted with BxPC3 human pancreatic cancer in example 2.
FIG. 3 is a photograph showing the effect of oroxylin on the growth inhibition of human pancreatic cancer BxPC3 xenograft tumor in nude mice in example 2.
Detailed Description
The present invention is described in further detail below with reference to specific examples, but the present invention should not be construed as being limited thereto. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention. The experimental methods and reagents of the formulations not specified in the examples are in accordance with the conventional conditions in the art.
Unless otherwise indicated, the raw materials and reagents used in the following examples are all commercially available products or can be prepared by known methods.
Example 1
Influence of oroxylin on growth activity of pancreatic cancer cell strain BxPC-3 cells
1. Experimental Material
1.1 reagents
(1) Oroxylin (C)16H12O5Molecular weight: 284.263) was supplied by university of Chinese pharmacy in the form of pale yellow powder with a purity of greater than 99%, and the drug powder was prepared as a 0.1M stock solution with dimethyl sulfoxide (DMSO) prior to use and stored at-20 ℃. The required concentration was prepared just before use in RPMI-1640 medium containing 10% fetal bovine serum.
(2) Cell culture reagent
RPMI-1640 medium: product of GIBCO, usa. Dissolving 10.4g of RPMI-1640 powder in 1000mL of sterilized distilled water, adding 2.0g of NaHCO3Adjusting the pH value to 7.3-7.4, filtering and sterilizing by a 0.22 micron microporous filter membrane, and storing in a refrigerator at 4 ℃. Complete medium was prepared by adding 10% heat-inactivated fetal bovine serum, 100U/mL penicillin and 100mg/L streptomycin prior to use.
② fetal bovine serum: product of GIBCO, usa. Inactivating in 56 deg.C water bath for 30min, subpackaging, and storing in-20 deg.C low temperature refrigerator.
③ PBS buffer solution: weighing 8.0g of NaCl, 0.20g of KCl and Na2HPO4·H2O 1.56g、KH2PO4.2.0g, dissolved in 1000mL of triple distilled water, autoclaved, and stored in a refrigerator at 4 ℃.
0.02% EDTA solution: weighing 20mg of EDTA powder, dissolving the EDTA powder in 100mL of PBS buffer solution, stirring at a low speed, adjusting the pH value to 7.3-7.4, sterilizing by high pressure steam, and storing in a refrigerator at 4 ℃.
0.25% trypsin: product of GIBCO, usa. Weighing pancreatin powder 0.25g, dissolving in PBS buffer solution 100mL, filtering with 0.22 μm microporous membrane for sterilization, and storing in refrigerator at 4 deg.C.
(3) Cell growth activity inhibition detection related reagent
MTT powder and DMSO solutions were purchased from Sigma-Aldrich.
1.2 cell lines
Pancreatic cancer cell line BxPC3 was purchased from shanghai academy of sciences. Cells were cultured in RPMI-1640 medium containing 100U/mL penicillin, 100mg/mL streptomycin, and 10% fetal bovine serum.
2. Experimental methods
MTT assay
MTT solution can be reduced into blue-violet crystal formazan by mitochondrial dehydrogenase in living cells, and the DMSO can dissolve the formazan, and the color shade of the formed solution is in direct proportion to the cell activity, so that the cell activity can be detected. Cells were aligned at 1X 105Culturing each/mL of cells in a 96-well enzyme label plate at a cell density of 100 mu L in each well, placing the cells in an incubator for 24h, and adding 100 mu L of oroxylin with a specified concentration; continuously placing the cells to which the medicine is administered in an incubator for 24 hours, and adding 20 mu L of MTT solution into each hole; after further incubation for 4h, the supernatant was removed, 100. mu.L DMSO was added to each well, the mixture was shaken in a micro-shaker, and after the crystals were completely dissolved, the absorbance was measured at 570 nm. And (3) after the detected light absorption value is finished, calculating the growth inhibition rate of the drug to the cells according to the following formula:
3. results of the experiment
The influence of the oroxylin on the growth activity of the pancreatic cancer cell strain BxPC3 within 24h is detected by an MTT (methyl thiazolyl tetrazolium) experiment. As shown in figure 1, the growth activity (Cellhibition) and half-maximal inhibition rate (IC) of BxPC3 cells can be remarkably inhibited after the Oroxylin (Oroxylin A) treatment for 24 hours50) At 121.09 μ M, this result preliminarily confirmed the effect of oroxylin against pancreatic cancer.
Example 2
Influence of oral oroxylin on growth activity of pancreatic cancer cell strain BxPC-3 cells
By constructing a nude mouse xenograft tumor model of human pancreatic cancer cells BxPC3, the 300mg/kg oroxylin group is found to have good anti-tumor effect and does not have obvious inhibition effect on the weight of experimental animals.
1. Experimental Material
1.1 test drugs
Oroxylin (C)16H12O5Molecular weight: 284.263) is provided by university of Chinese pharmacy, and has light yellow powder with purity of more than 99%. The oroxylin raw material medicine is dispersed in 0.5% CMC-Na after being pulverized by airflow, the concentration of the prepared medicine is 15mg/mL, the administration volume is 0.4mL/20g, namely the administration concentration is 300 mg/kg. Diluting with medium-low dosage multiple ratio.
1.2 Experimental animals
Source, species, strain: BALB/c nude mice, obtained from Kyowa Kavens laboratory animals Co., Ltd. (laboratory animal production license: SCXK (threo) 2016-0010).
The age in days: 4-5 weeks.
Sex: and (4) female.
1.3 grouping and dose setting of laboratory animals
TABLE 1 Experimental animal groups and dose settings
| Group of | Medicine | Dosage form | Mode of administration | Number of animals |
| Negative control group | Physiological saline | -- | p.o. | 6 |
| Drug treatment group | Oroxylin | 300mg/kg | Once in p.o.2 |
6 |
1.4 transplantation tumor
A human pancreatic cancer BxPC3 nude mouse transplantation tumor is established by inoculating a human pancreatic cancer BxPC3 cell strain under the axillary skin of a nude mouse. The cell inoculation amount is 5 multiplied by 106One/only.
2. Experimental methods
The human pancreatic cancer BxPC3 cell strain in logarithmic growth phase is prepared into 5 × 10 cells under aseptic condition7The cell suspension was inoculated subcutaneously in the right axilla of nude mice at 0.1 mL. Measuring the diameter of the transplanted tumor of the nude mouse by using a vernier caliper until the tumor grows to 100-300 mm3Animals were then randomized into groups. The antitumor effect of the test object is dynamically observed by using a method for measuring the tumor size. Tumor diameter was measured 1 time every 3 days. After 21 days, the mice were sacrificed and the tumor mass was surgically removed and weighed.
The formula for Tumor Volume (TV) is: TV 1/2 × a × b2Wherein a and b represent length and width, respectively.
Calculating Relative Tumor Volume (RTV) according to the measurement result, wherein the calculation formula is as follows: RTV ═ Vt/V0In which V is0When administered separately from the cage (i.e. d)0) Measurement of the resulting tumor volume, VtFor the tumor volume at each measurement
The evaluation index of the antitumor activity is relative tumor proliferation rate T/C (%), and the calculation formula is as follows:
The tumor inhibition rate is calculated by the formula:
3. Results of the experiment
As shown in figure 2, figure 3 and table 2, oroxylin is administrated by gavage at 300mg/kg, 1 time every 2 days, and after 21 days of administration, the tumor inhibition rate of human pancreatic cancer BxPC3 nude mouse transplantation tumor reaches 52.76%.
Compared with a blank control group, the oroxylin 300mg/kg group has a significant influence on the body weight of the experimental animal (p is less than 0.05), and other groups have no statistical difference on the influence on the body weight of the experimental animal.
TABLE 2 inhibition of human pancreatic cancer BxPC3 nude mouse xenograft tumor growth by oroxylin (X + -SD)
P <0.05, P <0.01, compared to the blank control group
The invention verifies the cell inhibition effect of oroxylin on pancreatic cancer through MTT experiments and nude mouse ectopic tumor inhibition experiments, proves that oroxylin has good application prospect in treating pancreatic cancer, and can be used for preparing pancreatic cancer treatment medicines.
Claims (2)
1. Application of oroxylin in preparation of pancreatic cancer treatment medicines.
2. Application of oroxylin in preparing oral medicine for treating pancreatic cancer is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111085855.5A CN113730396A (en) | 2021-09-16 | 2021-09-16 | Application of oroxylin in preparation of pancreatic cancer treatment medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111085855.5A CN113730396A (en) | 2021-09-16 | 2021-09-16 | Application of oroxylin in preparation of pancreatic cancer treatment medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113730396A true CN113730396A (en) | 2021-12-03 |
Family
ID=78739263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111085855.5A Pending CN113730396A (en) | 2021-09-16 | 2021-09-16 | Application of oroxylin in preparation of pancreatic cancer treatment medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113730396A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108309966A (en) * | 2018-05-16 | 2018-07-24 | 中国人民解放军第二军医大学 | Qroxylin A is used as the purposes of transketolase inhibitor |
-
2021
- 2021-09-16 CN CN202111085855.5A patent/CN113730396A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108309966A (en) * | 2018-05-16 | 2018-07-24 | 中国人民解放军第二军医大学 | Qroxylin A is used as the purposes of transketolase inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3257508A1 (en) | Application of chlorogenic acid in preparing medicines for treating melanoma and medicines for treating melanoma | |
| CN108685892B (en) | Application of chlorogenic acid and composition thereof in preparing medicine for treating squamous cell carcinoma | |
| US9211308B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| CN112675131A (en) | Oroxylin pharmaceutical composition and application thereof in preparation of liver cancer drugs | |
| CN113730396A (en) | Application of oroxylin in preparation of pancreatic cancer treatment medicine | |
| CN109793727A (en) | A kind of pharmaceutical composition and its application of effective anti-malignant tumor | |
| CN110575450B (en) | Application of 2, 5-furandimethanol in preparation of antitumor drugs | |
| WO2022110568A1 (en) | Use of vitamin c and disulfiram in preparing anti-tumor combination drug | |
| CN112891341A (en) | Application of GL-V9 and anthracycline antibiotics in preparation of leukemia treatment drug | |
| CN113663081A (en) | Application of oroxylin and PD-1/PD-L1 inhibitor in preparation of liver cancer treatment drug | |
| CN104055786B (en) | The application in preparation preventing and treating tumour medicine of medicagenic acid-3-O-β-D-pyranglucoside, medicagenic acid and salt thereof | |
| CN112076216A (en) | Application of arsenic trioxide in treating gastrointestinal stromal tumor | |
| CN117045639B (en) | Pharmaceutical composition for treating gastric cancer and application thereof | |
| CN114642675B (en) | Application of L-sorbose in preparing medicine for treating tumor | |
| CN105477068B (en) | Preparation method and application of active site of mulberry branch and leaf | |
| CN115089570B (en) | Pharmaceutical composition for treating tumors and preparation and application thereof | |
| CN115531364B (en) | Microbial metabolite preparation for preventing or treating rotavirus infection and application thereof | |
| CN111632149B (en) | Pharmaceutical composition for treating lung cancer and preparation thereof | |
| CN112043717B (en) | Pharmaceutical composition for treating lung cancer and preparation thereof | |
| CN112545979B (en) | Perfusion gel for preventing postoperative recurrence of bladder cancer and preparation method and application thereof | |
| CN107789466A (en) | A kind of pharmaceutical composition for being used to treat tumour | |
| CN104873513B (en) | A kind of pharmaceutical composition and detection method for suppressing lung carcinoma cell transfer | |
| CN114617885A (en) | Application of isoliensinine in preparation of drugs for treating solid tumors | |
| CN116942676A (en) | Application of Baloxavir in preparation of antitumor drugs | |
| CN117582448A (en) | Use of digoxin in preparation of medicine for preventing or treating adrenocortical carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211203 |
|
| RJ01 | Rejection of invention patent application after publication |